Antengene Corporation Limited

Antengene Corporation Limited is a global, R&D-driven, commercial-stage biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing innovative first-in-class and/or best-in-class therapeutics. The company's mission is to treat patients beyond borders by providing advanced medicines for hematologic malignancies, solid tumors, and autoimmune diseases. Antengene's primary operational base is in Shanghai, China, with additional R&D and manufacturing facilities in Hangzhou and Shaoxing, China, and operations in other global locations including Cambridge, Massachusetts, Melbourne, Australia, Singapore, Seoul, South Korea, and Hong Kong.

The company's key commercialized product is XPOVIO® (selinexor), an oral Selective Inhibitor of Nuclear Export (SINE) compound approved for various hematological malignancies and solid tumors, including relapsed/refractory multiple myeloma and diffuse large B-cell lymphoma. XPOVIO® has received approvals in multiple Asia Pacific markets and is included in national insurance schemes in several of these regions. Antengene's pipeline includes several in-house discovered programs such as ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), and ATG-125 (B7-H3 × PD-L1 bispecific ADC). The company also leverages its proprietary AnTenGager® T-cell engager (TCE) 2.0 platform for developing novel therapies, including ATG-201 for autoimmune diseases.

Led by Founder, Chairman, and CEO Dr. Jay Mei, Antengene announced its 2025 full-year results in March 2026, highlighting the validation of its AnTenGager® platform through its first TCE out-licensing deal, marking an inflection point towards profitability in 2026. This includes a global licensing agreement with UCB for ATG-201, which involves an upfront payment and potential milestone payments and royalties. The company is also advancing its late-stage clinical programs, with plans to initiate a pivotal Phase III monotherapy trial for ATG-022 in gastric cancer in the second half of 2026. Antengene continues to expand the commercial footprint of XPOVIO®, which is approved in 10 APAC markets and covered by national insurance in five.